The aim of this study was to assess the susceptibility of Bcc to ceftazidime/avibactam and standard drugs for treatment in people with CF and to determine the respective genomic determinants of resistance.
| Accession | PRJNA748922 |
| Data Type | Genome sequencing and assembly |
| Scope | Multispecies |
| Publications | Schaumburg F et al., "Susceptibility of Burkholderia cepacia Complex to Ceftazidime/Avibactam and Standard Drugs of Treatment for Cystic Fibrosis Patients.", Microb Drug Resist, 2022 May;28(5):545-550 |
| Submission | Registration date: 22-Jul-2021
University Hospital Muenster |
| Relevance | Medical |
Project Data:
| Resource Name | Number
of Links |
|---|
| Sequence data |
| Nucleotide (total) | 148 |
| WGS master | 27 |
| Genomic DNA | 121 |
| Protein Sequences | 219458 |
| Publications |
| PubMed | 1 |
| Other datasets |
| BioSample | 64 |
| Assembly | 64 |